Abstract: A female connector member adapted to quickly couple with a male connector member includes a connector body having a fluid passageway and opening for receiving the male connector member, a slot defined in a wall of the female connector member, and a verification tab received in the slot and slidingly movable within the slot along a direction perpendicular to an axial direction in which the male connector is insertable, wherein the verification tab has an edge contoured to cause lateral movement of the verification tab from a first position in which indicia on the verification tab is concealed to a second position in which the indicia is visibly exposed when engaged by a projecting feature of the male connector member.

Abstract: The present disclosure provides improved compositions for the homology directed repair of the human globin locus for the prevention, treatment, or amelioration of at least one symptom of a hemoglobinopathy.

Abstract: Photosensitive polymer formulations, materials and uses of such materials are disclosed. Embodiments of the present disclosure provide photosensitive polyimide materials having chain extenders and formulations thereof that improve elongation and formability of the polyimide materials, and methods of making such polymer materials.

Abstract: Devices including high-aspect ratio electroplated structures and methods of forming high-aspect ratio electroplated structures are described. A method for manufacturing metal structures includes providing a substrate having a metal base characterized by a height to width aspect ratio A/B and electroplating a metal crown on the base to form the metal structure with a height to width aspect ratio A/S greater than the aspect ratio A/B of the base.

Abstract: A fitting for use in a manifold or other tubular assembly includes a core and at least one tubular coupling sleeve slidably and sealingly fitted over a distal end of the core to accommodate predetermined tolerances in the relative positions of fluid ports connected with the tubular assembly. Features are provided to limit the range of motion to the predetermined tolerances and to prevent disassembly of the coupling sleeve from the core of the fitting.

Abstract: A duct includes an inner tube configured to have fluid flow through to be transported and an outer tube surrounding the inner tube. The outer tube defines, in its interior, a plurality of auxiliary channels, which extend in the longitudinal direction of the outer tube and are designed to contain or have a further auxiliary fluid flow through, which is configured to thermally interact with the fluid to be transported.

Abstract: The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the HLA antigens or alleles typed in the patient; and administering the selected pool of expanded human cord blood stem/progenitor cell samples to the patient. Methods for obtaining the pools of expanded human cord blood stem/progenitor cell samples, banks of frozen pools of expanded human umbilical cord blood stem/progenitor cell samples, and methods for producing such banks are also provided herein.

Abstract: The present disclosure relates to immunomodulatory fusion proteins containing an extracellular binding domain and an intracellular signaling domain, wherein binding of a target can generate a modulatory signal in a host cell, such as a T cell. The present disclosure also relates to uses of immune cells expressing such immunomodulatory fusion proteins to treat certain diseases, such as cancer or infectious disease.

Abstract: The present disclosure provides reagents and methods for treating disease using modified immune cells (e.g., T cell comprising CAR or TCR) in combination with an agent associated with induction of immunogenic cell death (ICD) and optionally further in combination with an agent that specifically binds to and/or inhibits an immune suppression component and/or an agonist of an immune stimulatory molecule.

Abstract: Engineered trimeric CD70 proteins for use in ex vivo T cell manufacturing are described. Use of the proteins during manufacturing creates expanded T cell populations with enhanced properties such as earlier proliferation in culture; selective expansion of nave and memory T cell subsets; longer persistence in vivo following administration to a subject; and improved therapeutic effect. Use of the proteins as therapeutics provide anti-cancer and anti-viral effects. The proteins can also be used as agonistic cell culture reagents in in vitro uses.

Abstract: Methods and kits to distinguish normal or Barrett's esophageal samples from high grade dysplasia (HGD), esophageal adenocarcinoma (EAC), or junctional adenocarcinoma (JCA) samples are described. The methods and kits utilize the methylation status of epigenetic markers, such as cg6522, POU3F1, YPEL3, and/or MAFB.

Abstract: Small cell lung cancer specific chimeric antigen receptor comprising: an antigen-binding domain capable of specifically binding an antigen selected from Tables 1A, 1B, 2A, 2B and 4 and/or that specifically binds to or interacts GAD65, PTPRU, TFRC and GABA-b. A method for treating a subject suffering from SCLC comprising, introducing into the subject a therapeutically effective amount of a T lymphocyte comprising a chimeric antigen receptor. An antigen binding molecule, comprising: an antigen-binding domain capable of specifically binding an antigen selected from Tables 1A, 1B, 2A, 2B and 4 and/or that specifically binds to or interacts GAD65, PTPRU, TFRC and GABA-b. A method of detecting an SCLC tumor in a subject.

Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with chronic lymphocytic leukemia (CLL). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods involve prior administration of a lymphodepleting therapy, such as prior administration of fludaribine and/or another lymphodepleting chemotherapeutic agent, for example cyclophosphamide. In some embodiments, features of the methods include an increase in complete remission, overall survival and/or progression free survival of subjects treated in accord with the provided methods.

Abstract: The present disclosure provides compositions and methods that rapidly and selectively modify cells of the immune system to achieve therapeutic objectives. The methods can be practiced in vivo and any cell type that expresses a known marker can be targeted for a therapeutic objective.

Abstract: The present disclosure provides compositions and methods for targeting a neoantigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as T cell receptors bind to a neoantigen:HLA complex. Disclosed binding proteins are highly sensitive to antigen, capable of inducing activation of host T cells at low concentrations of peptide antigen. In certain embodiments, binding proteins of the present disclosure are non-alloreactive against, are substantially non-alloreactive against, and/or have a low risk of alloreactivity against (i) amino acid sequences from the human proteome and/or (ii) against human HLA alleles. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers.

Abstract: The use of luteinizing hormone receptor (LHR) binding agents and luteinizing hormone (LH) agonists to enrich for primitive hematopoietic stem cell (pHSC) populations, to target pHSC for ablation, and/or to expand pHSC populations are described. The methods can be used to prepare therapeutic hematopoietic stem cell (HSC) populations, to prepare patients for therapeutic HSC transplants, and/or to treat malignancies, such as those associated with hyperproliferative HSC.

Abstract: Chimeric antigen receptor (CAR) with a binding domain that binds STEAP1 are disclosed. The CAR disclosed herein can be used in the treatment of prostate cancer, the Ewing family of tumors (EFT), bladder cancer, ovarian cancer, and rhabdomyosarcoma. The CAR disclosed herein can bind and elicit cytotoxic effects even in low antigen density conditions.

Abstract: A fluidic connection and fluid heating device for a fluid circuit, in particular for a motor vehicle, the device comprising a one-piece tubular body of plastic or composite material comprising at least one internal annular surface defining a fluid flow duct from an inlet to an outlet of the body and at least one external annular surface extending around the duct and on which is located at least one resistive heating element, wherein the resistive heating element is a resistive circuit which is formed in situ on the annular surface.

Abstract: Newborn screening for primary immunodeficiencies, cystinosis, and Wilson disease is described. The newborn screening can detect these disorders from dried blood spots already routinely collected at the time of birth. Early detection of these disorders will greatly improve patient outcome as each of them can be fatal once symptoms emerge.

Abstract: DNA hypomethylation as a predictive marker for cancer therapy is described. The susceptibility of hypomethylated cancers to particular treatments, for example to AKT inhibitors and anthracyclines is described. The described susceptibilities can be used to direct enrollment of subjects into appropriate clinical trials and to guide treatment selection and administration based on global DNA methylation level.